Archives

Synchrony Puts Teachers First This Financial Literacy Month with $2 Million Commitment to Bring Training, Tools, and Financial Literacy Labs to U.S. High Schools

B Company accelerates investment in personal finance education in classrooms nationwide Key Highlights Synchrony announces $2 million in Empowering Financial Future grants and in-kind donations,… Login to continue reading Login…

Read MoreSynchrony Puts Teachers First This Financial Literacy Month with $2 Million Commitment to Bring Training, Tools, and Financial Literacy Labs to U.S. High Schools

THORNE DEBUTS WOMEN’S HEALTH CAMPAIGN WITH MISTY COPELAND AND LANA CONDOR, INTRODUCING NEW CLINICALLY FORMULATED PRODUCTS

B Omni-channel campaign connects women’s lived experiences to biological clarity – grounded in science-backed support NEW YORK, April 6, 2026 /PRNewswire/ — Thorne, the leader in… Login to continue reading Login…

Read MoreTHORNE DEBUTS WOMEN’S HEALTH CAMPAIGN WITH MISTY COPELAND AND LANA CONDOR, INTRODUCING NEW CLINICALLY FORMULATED PRODUCTS

If you purchased one or more Tom’s of Maine® toothpaste products within the United States, between November 21, 2020 through March 6, 2026, you may be eligible to receive a payment from a class action settlement.

B CENTRAL ISLIP, N.Y., April 6, 2026 /PRNewswire/ —  A Federal court authorized this notice (the “Notice”). This is not a solicitation from a lawyer.… Login to continue reading Login…

Read MoreIf you purchased one or more Tom’s of Maine® toothpaste products within the United States, between November 21, 2020 through March 6, 2026, you may be eligible to receive a payment from a class action settlement.

Alar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

B By reducing dissociation and sedation risk, ALA-3000 may eliminate the ≥2-hour post-dose monitoring requirement, reducing clinic operating costs, improving patient throughput, and supporting a… Login to continue reading Login…

Read MoreAlar Breaks Key Barriers in Ketamine Therapy with Positive Phase 1 Results for Long-Acting Injectable ALA-3000 for Treatment-Resistant Depression

Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch

B Strengthens balance sheet to support commercial readiness and planned U.S. launch of AD109 oral pill for the treatment of Obstructive Sleep Apnea (OSA) On… Login to continue reading Login…

Read MoreApnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch